Thomas R. Hickey

Thomas R. Hickey

Auto-generated profile, based on publicly available information

Thomas R. Hickey

Anesthesiology, Yale School of Medicine, New Haven, Connecticut, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
THThomas R Hickey
Thomas R Hickey
GCGabriel P A Costa
Gabriel P A Costa
DODebora Oliveira
Debora Oliveira
APAlexandra Podosek
Alexandra Podosek
AAAudrey Abelleira
Audrey Abelleira
JAJoao P De Aquino
Joao P De Aquino
Background/Importance: Opioids continue to play a key role in managing acute postoperative pain, but their use contributes to adverse outcomes. Buprenorphine may offer effective analgesia with a superior safety profile. Objective: To compare the efficacy and safety of buprenorphine with other opioids for acute postoperative pain management in adults. Evidence review: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched from inception to February 2024. Randomized controlled trials comparing buprenorphine with other opioids for acute postoperative pain management in adults were included. Of 2421 records identified, 58 studies met inclusion criteria. Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analysis was performed using Stata/BE V.18. The primary outcome was pain intensity. Secondary outcomes included rescue analgesia use, duration of analgesia, and adverse effects. Findings: Analysis of 41 comparisons (2587 participants) showed buprenorphine significantly reduced pain intensity compared with all other opioids (Hedges’s g=−0.36, 95% CI=−0.59 to −0.14, p<0.001, 95% prediction interval (PI)=−1.70 to 0.97). This effect persisted when compared with full agonist opioid (FAO) alone (standardized mean difference −0.34, 95% CI=−0.59 to −0.10, p<0.001, 95% PI=-1.76 to 1.07). Patients receiving buprenorphine were less likely to require rescue analgesia (OR=0.40, 95% CI=0.26 to 0.63, p<0.001, 95% PI=0.12 to 1.36). Mean duration of analgesia was 8.5 hours (SD 1.84). There were no significant differences in other adverse effects including nausea and respiratory depression. Inconsistency was significant for pain intensity (I 2 =86.28%, 95% CI=81.55% to 88.99%) and moderate for rescue analgesia (I 2 =38.93%, 95% CI=1.44% to 64.37%). Risk of bias was low in 19 studies, with some concerns in 37 studies, and high in two studies. Conclusions: Buprenorphine demonstrated superior efficacy in managing acute postoperative pain compared with FAOs, with a favorable safety profile and longer duration of action. These findings support the use of buprenorphine as a first-line opioid analgesic for acute postoperative pain management requiring opioid analgesia, potentially reducing opioid-related harm in the postoperative period. PROSPERO registration number: CRD42023447715.

1 December 2024 in Journal of Opioid Management
Verified
Journal Article
Closed access
PDF file
THThomas Hickey
Thomas Hickey
GAGregory Acampora
Gregory Acampora
Buprenorphine was synthesized in the 1960s as a result of a search for a safe and effective opioid analgesic. Present formulations of buprenorphine are approved for the treatment of both acute and chronic pain. Its long duration of action, high affinity, and partial agonism at the μ-opioid receptor have established it as a mainstay treatment for opioid use disorder (OUD). Full agonist opioids (FAOs) remain a primary choice for perioperative pain in both opioid-naïve and opioid-tolerant patients despite well-known harms and new emphasis on multimodal analgesia strategies prioritizing nonopioid analgesics. We review the evidence supporting the use of buprenorphine as an effective analgesic alternative to more commonly prescribed FAOs in acute and chronic pain management. For the patient prescribed buprenorphine for OUD, prior conventionalism advised temporary discontinuation of buprenorphine preoperatively; this paradigm has shifted toward continuing buprenorphine throughout the perioperative period. Questions remain whether dose adjustments may improve patient outcomes.

9 January 2025 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Open access
PDF file
THThomas R Hickey
Thomas R Hickey
GCGabriel P A Costa
Gabriel P A Costa
VAVictor Javier Avila-Quintero
Victor Javier Avila-Quintero
JAJoao P De Aquino
Joao P De Aquino
Opioids continue to play a role in postoperative pain management and continue to result in predictable harm to patients including persistent use and overdose.1 Buprenorphine, a partial agonist opioid, has an almost 60-year track record of efficacy in acute pain management. However, in contemporary practice, it is rarely used for this purpose and is better known as an essential medicine for opioid use disorder. In this systematic review and meta-analysis of randomized controlled trials, the authors aimed to broaden the understanding of buprenorphine’s efficacy versus opioids as a class in the treatment of acute postoperative pain in adults. Inclusion criteria were met for 58 studies.

7 July 2025 in Journal of Pain & Palliative Care Pharmacotherapy
Verified
Journal Article
Closed access
AAAudrey Abelleira
Audrey Abelleira
THThomas R. Hickey
Thomas R. Hickey
Opioids continue to be relied on to treat postoperative pain and continue to result in harms ranging from pruritis to overdose. The partial agonist opioid buprenorphine was synthesized in the 1960s as result of a search for a safe and effective opioid analgesic. While formulations of buprenorphine are approved for the treatment of pain, it is more commonly known as a medication for opioid use disorder. However, there is increasing interest in employing buprenorphine as a front-line perioperative opioid analgesic. We review the continued reliance on full agonist opioids and associated harms, highlight key efficacy and safety advantages of buprenorphine compared to usual care opioids, and describe the evolution of our consideration of buprenorphine for acute perioperative pain management. We then describe the process by which we worked within our institution to arrive at a twice daily buccal film and describe the clinical pathway ultimately implemented, providing details on training of staff, order set development, and surgical populations included. Buprenorphine presents a promising opportunity to reduce opioid harms while potentially improving pain outcomes after surgery. Our experience suggests that the buccal formulation possesses unique advantages for perioperative administration. Future directions will inform buprenorphine's impact on key pain and opioid-related outcomes.

13 May 2025 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
RHRyan Hopkins
Ryan Hopkins
RMR Ross MacLean
R Ross MacLean
BPBrian Pittman
Brian Pittman
AMAndres Missair
Andres Missair
RGRobert R Gaiser
Robert R Gaiser
THThomas R Hickey
Thomas R Hickey

17 May 2025 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
VAVictoria Ameral
Victoria Ameral
THThomas R. Hickey
Thomas R. Hickey
ERErin Dawna Reilly
Erin Dawna Reilly
JPJessica A Patterson
Jessica A Patterson
MSMehmet Sofuoglu
Mehmet Sofuoglu
A critical challenge in providing effective medical care for individuals in opioid agonist treatment (OAT) for opioid use disorder is the effective management of acute and chronic pain. While pain commonly co-occurs with opioid use disorder, there is limited research to guide effective management of pain in this population. We first provide an overview of the etiology and treatment of acute and chronic pain, highlighting areas of complexity for patients receiving OAT. We then describe the search strategy, which involved a date-inclusive search for relevant terms in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. After summarizing the results of this search on the evidence for pharmacological and behavioral treatments of acute and chronic pain for individuals on OAT, we conclude with a discussion of these finding and a summarized expert opinion on the state of the evidence. The evidence suggests that while research on effective treatment of acute and chronic pain in individuals in OAT is limited, promising work is ongoing to translate existing treatments, particularly behavioral treatments for chronic pain, to support this population. However, further research is warranted, particularly regarding pharmacological options.